![Craig C. Estwick](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Craig C. Estwick
Presidente presso Nexpep Pty Ltd.
Profilo
Craig C.
Estwick currently works at Nexpep Pty Ltd., as Chairman from 2009.
Mr. Estwick also formerly worked at ImmusanT, Inc., as Director and Deloitte Consulting Pty Ltd., as Partner in 2000.
Mr. Estwick received his graduate degree in 2003 from The University of Queensland.
Posizioni attive di Craig C. Estwick
Società | Posizione | Inizio |
---|---|---|
Nexpep Pty Ltd. | Presidente | 01/01/2009 |
Precedenti posizioni note di Craig C. Estwick
Società | Posizione | Fine |
---|---|---|
Deloitte Consulting Pty Ltd.
![]() Deloitte Consulting Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Deloitte LLP (New York), Deloitte Consulting Pty Ltd. provides cyber security consulting services. The company is based in Sydney, Australia. | Corporate Officer/Principal | 01/01/2000 |
ImmusanT, Inc.
![]() ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Direttore/Membro del Consiglio | - |
Formazione di Craig C. Estwick
The University of Queensland | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
ImmusanT, Inc.
![]() ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Health Technology |
Nexpep Pty Ltd. | |
Deloitte Consulting Pty Ltd.
![]() Deloitte Consulting Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Deloitte LLP (New York), Deloitte Consulting Pty Ltd. provides cyber security consulting services. The company is based in Sydney, Australia. | Commercial Services |
- Borsa valori
- Insiders
- Craig C. Estwick